Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.490
+0.290 (13.18%)
At close: Sep 5, 2025, 4:00 PM
2.480
-0.010 (-0.40%)
Pre-market: Sep 8, 2025, 8:52 AM EDT
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 838 employees as of December 31, 2024. The number of employees increased by 281 or 50.45% compared to the previous year.
Employees
838
Change (1Y)
281
Growth (1Y)
50.45%
Revenue / Employee
$288,216
Profits / Employee
-$465,300
Market Cap
901.02M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 838 | 281 | 50.45% |
Dec 31, 2023 | 557 | 54 | 10.74% |
Dec 31, 2022 | 503 | 184 | 57.68% |
Dec 31, 2021 | 319 | 78 | 32.37% |
Dec 31, 2020 | 241 | 93 | 62.84% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IOVA News
- 10 days ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 16 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25 - Seeking Alpha
- 20 days ago - Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma - GlobeNewsWire
- 4 weeks ago - Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 - GlobeNewsWire
- 6 weeks ago - Here's why Iova stock surged 32% today and why the rally might not be over - Invezz
- 7 weeks ago - Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha